Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies ...

BridgeBio Pharma Inc. BBIO on Wednesday announced a recent presentation of interim results from its Phase 3 FORTIFY trial for BBP-418, a treatment for limb-girdle muscular dystrophy type 2I/R9.

Researchers discovered that R. inulinivorans plays an important role in muscle strength and could act as a probiotic candidate for nutraceutical interventions targeting age-related muscle-wasting ...

Solid Biosciences (SLDB) stock retains a "Strong Buy" rating, driven by robust interim data for SGT-003 in pediatric Duchenne ...

A rare medical condition, Fibrodysplasia Ossificans Progressiva (FOP), also known as 'Stone Man Syndrome,' has been identified for the first time in Jaisalmer, Rajasthan. A 9-year-old child is ...

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) belong to a spectrum of neurodegenerative diseases with overlapping symptoms, characterized by muscle wasting, paralysis, dementia ...

Nanogel gives stem cells room to breathe Nanogel integrated spheroids increase cell retention and repair injured swallowing muscles. (Nanowerk News) Swallowing is a ...

The latest figures from the Department for Work and Pensions show over 3.9 million people across England and Wales are now receiving Personal Independence Payment (PIP), worth up to £749 a month for ...

Mutations that cause spinal muscular atrophy (SMA) may lead to abnormalities in the development of cells in the spinal cord, a study found.

A growing body of research is describing the anti-inflammatory and immunomodulatory benefits of exercise, according to data presented at the Basic and Clinical Immunology for the Busy Clinician ...

Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary ...